Pfiz­er is dou­bling down on its com­mit­ment to Chi­na as the com­pa­ny con­tin­ues to face ac­tivist pres­sure around its ...

The head of As­traZeneca’s op­er­a­tions in Chi­na has been de­tained by au­thor­i­ties there, the com­pa­ny con­firmed.

Sign up to read this article for free. Get free access to a limited number of articles, plus choose newsletters to get ...

Coming out of Covid, the vaccine market appeared to experience a renaissance as the innovations of the pandemic unleashed new ...

Welcome to Endpoints News’ manufacturing briefs, where we bring you essential news on new builds, collaborations, recalls and more. Coherus is resuming the supply of its ...

Aurinia Pharmaceuticals is reducing 45% of its workforce and is bringing in a new board member as part of a broader restructuring. The company ...

Genmab is culling a trio of early oncology assets to focus on upcoming milestones for its late-stage programs that include an ...

Plus, news about ADC Therapeutics, Celldex and Viracta Therapeutics: Geron inks up to $375M royalty and debt deal: The company now has a $125 million deal ...

Denali revealed new topline data Wednesday for an early-stage program that's a part of the FDA’s Operation Warp Speed for rare diseases. The program, DNL126, is an ...

Demis Hassabis is pursuing one of the boldest efforts of bringing AI into biotech, building out the Alphabet-backed startup Isomorphic Labs over the past three ...

After a year of customer pullbacks, biologics CDMO Avid Bioservices will be taken private by GHO Capital Partners and Ampersand Capital Partners in a deal worth $1.1 billion. “In evaluating ...

While there’s a lot of potential for AI in health tech, it will soon be commoditized, investor Greg Yap told Endpoints News in an interview on the sidelines of the ...